The aim of the study was to compare the urinary excretion data and bioavailability of two 500 mg amoxicillin capsules formulations in healthy Bangladeshi subjects under fasting condition and evaluate the ethnic variations in drug disposition. Twenty-four subjects were enrolled into this single-dose, randomized, open-label, twoway cross over study. A washout period of one week was allowed between two treatments. Following oral administration, urine samples were collected at different time intervals and were analyzed using a validated HPLC method with UV detection. The pharmacokinetic parameters for two formulations were calculated by noncompartmental method using the software Kinetica and statistical analysis was done for the evaluation of bioequivalence. The pharmacokinetic analysis indicated that the kinetic disposition of two formulations was similar. This was evident when the mean (± standard deviation) values of the various pharmacokinetic parameters were compared. No significant difference between two formulations was found when analyzed by paired t-test and ANOVA. Therefore it can be concluded that the test product (SK-mox ® ) is bioequivalent to the reference product (Amoxil-Bencard ® ) based on the US FDA's regulatory definition. Moreover, an ethnic variation was observed following 64.34% cumulative urinary recovery of amoxicillin over 12 hours when compared with other studies.
INTRODUCTION
Amoxicillin, a well-known amino-substituted penicillin, enjoys widespread clinical use, not only because of its broad antibacterial spectrum but also because of its high oral bioavailability (>90%), which makes it relatively unaffected by food or by other concomitantly administered drugs. 1 The pharmaco-oral dose of 500 mg produces peak plasma concentration of about 10 µg/ml within 1 to 1.5 h, reaches adequate therapeutic concentrations in pleural, synovial, and ocular fluids, and accumulates in the amniotic fluid, but penetrates poorly into the central nervous system unless inflammation is present. 2 Excretion of amoxicillin is predominantly renal, and 75% of an intravenous dose is recovered in the urine within 6 hr, leading to very high urinary concentrations. [3] [4] [5] The drug's terminal half-life (t 1/2 ) of elimination is 1 to 1.5 hr. 2 Although a good number of generic oral formulations of amoxicillin are available in Bangladesh, the study on pharmaco-kinetic and bioavailability properties of these formulations is yet to be conducted with Bangladeshi population. Hence the current research was focused on it.
The USP 24 states that in bioequivalence studies, samples of an accessible biological fluid (blood or urine) are analyzed for drug and/or metabolite concentrations. 6 Use of blood for bioequivalence study is complex. Several reports indicate that urinary excretion data of drugs can be successfully used to compare the bioavailability of different formulations. 7 In order to obtain valid estimates of pharmacokinetics and bioavailability using urinary excretion data, the drug must be excreted in significant quantities in the urine and adequate sample of urine must be collected. Urinary excretion of amoxicillin is known to be almost 75% of the whole administered dose. Therefore, it will be a good method for bioavailability studies using urinary excretion data. Also, urine sampling, a non-invasive method of sampling from volunteers, may be useful for ease of compliance in recruiting volunteers to participate in bioavailability studies.
The study therefore, was conducted to investigate the pharmacokinetics and bioequivalence of 500 mg amoxicillin capsules namely, SK-mox ® as test product and Amoxil-Benacrd ® as reference product using urinary excretion data in healthy Bangladeshi volunteers and also to evaluate the ethnic variation based on these pharmacokinetic parameters. Clinical protocol (Informed consent, questionnaire, methods) was approved from Bangladesh Medical Research Council (BMRC) and each subject signed the consent form and filled the questionnaire prior to entry into the study. The volunteers were abstained from consumption of xanthene containing foods and beverages (chocolates, tea, coffee or coke) for 24 hr before administration of the dose and were fasted overnight (at least 10 hr). Preparation of urine sample for HPLC analysis. To 0.9 ml of urine samples, 0.1 ml of Cefaclor (1 mg/ml) was added as internal standard and vortexed for 15 seconds. Then 20 µl of the samples was injected into the column after filtering through 0.2 µ syringe filter to determine the concentrations of amoxicillin in urine samples using a validated HPLC method with UV detection.
MATERIALS AND METHODS

Materials
Drug
Standard preparation. Stock solutions of amoxicillin (1 mg/ml) and cefaclor (1 mg/ml) were prepared by dissolving each of the accurately weighed reference compound in diluent (potassium dihydrogen phosphate, pH = 5.0 ± 0.05 and acetonitrile at a ratio of 95:5). Calibration standards of 5, 10, 20, 50, 100, 200, 500 µg/mL for amoxicillin were prepared by serial dilutions of amoxicillin stock solution with blank urine and a fixed amount of cefaclor solution (internal standard). These samples were analyzed by the HPLC for the construction of calibration curve and method validation. Three levels of quality control working solutions, 5, 50 and 500 µg/ml, were also prepared which were used for precision, accuracy and stability testing. All working solutions were stored at 4ºC.
Chromatographic conditions. The Shimadzu (Tokyo, Japan) HPLC system consisted of a SCL10Avp system controller, two LC-8A pumps and a SPD-10Avp UV-VIS detector (Shimadzu Corporation; Tokyo, Japan). The sample analysis was conducted on a Nucleosil C 18 column (5µ , 4.6 X 250 mm, Varian, CA, USA), with a mixture of monobasic potassium phosphate buffer (pH 5.0 ±0.05) and acetonitrile (95:5), at a flow rate of 1.5 ml/min. The effluent was monitored at 230nm. The drug analysis data were acquired and processed using LC solution (Version 1.03 SP3, Shimadzu Corporation, Tokyo, Japan) software running under Windows XP on a Pentium PC. Quantification of amoxicillin in urine samples was obtained by plotting amoxicillin to internal standard (cefaclor) peak area ratio as a function of amoxicillin concentration.
Method validation.
Method validation was performed according to the protocol using a nominal concentration range of standards spanning from 5 to 500 µg/mL in urine to demonstrate the linearity, precision, accuracy, and stability of the method. Stability was confirmed for urine samples exposed to three freeze-thaw cycles, for samples stored for 48 hours at room temperature before injection, and for samples in long term storage at −40°C for up to 1 month.
Pharmacokinetic analysis. Pharmacokinetic parameters were calculated by non-compartmental analysis, according to the standard method with the software Kinetica (Version 4.4.1, Thermo Electron Corporation, UK). 10 For urine samples, the following input data were applied: start and end time of each urine collection interval (∆t), urine concentrations (C), and urine volumes (V) from which the midpoint of each collection interval and the renal excretion rate for each interval (R) was computed according to equation (I).
The maximal renal excretion rate (R max ) was observed and the midpoint of the respective collection interval associated with the maximal observed excretion rate (t max ) was also determined by visual inspection of the urinary excretion rate versus time profile curve. Area under the rate of amoxicillin excretion versus time curve (AURC 0−tz ) was calculated according to the linear trapezoidal rule. The renal elimination rate constant (K el ) was assessed by log-linear regression of the terminal segment of the excretion rate versus time curve and ln2 was divided by K el to calculate the terminal elimination half-life (t 1/2 ).
11 AURC 0−∞ was determined by the following equation.
Moreover, the observed total amount of amoxicillin recovered in urine from 0 to 12 h (Ae 0−12 ) and the fraction of orally administered amoxicillin excreted into urine within 12 h (f e /f) was calculated. The relative bioavailability was determined in terms of AURC 0-48 , AURC 0-α and Ae 0−12 from test formulation relative to reference formulation.
Statistical analysis. Student's t-test (paired) at 5% level of significance was used for testing the differences between the mean values obtained from two treatments using statistical software SPSS (Version 12.0, Chicago, IL). Pharmacokinetic parameters generated for the two treatments were also compared for significant differences due to dosing days (period effect), sequence (carryover effect), subjects within sequence, and formulation using ANOVA. 12 Large sample based 90% confidence intervals were estimated for parameters like R max , Ae 0−12 , AURC 0−12 , AURC 0−α , for the assessment of bioequivalence according to FDA guideline.
RESULTS AND DISCUSSION
Method validation. The HPLC method with UV detection used for drug quantification provides the appropriated sensitivity, specificity. The experimental limit of quantification of the method was 0.1 µg/ml, and the limit of detection was 0.05 µg/ml. Analysis of replicate blank serum samples indicated no interference peaks.
The calibration curve was linear over the concentration range of 5 to 500 µg/ml (r 2 >0.996).
The intra-day accuracy of the method for amoxicillin in urine ranged from 100.40 to 106.34%, while the intra-day precision ranged from 2.22 to 6.64%. The absolute recovery of amoxicillin from urine was 97.69%. No significant degradation of amoxicillin in urine, was observed during this period under the storage conditions.
Pharmacokinetic analysis.
No clinical or biological side effects were reported during the study. The plots of mean percent of cumulative amount of amoxicillin excreted over a period of 12 h versus mid-point of time intervals and mean log of excretion rates versus mid-point of time intervals for all volunteers are shown in Figure 1 and Figure 2 , respectively. From these figures, it is evident that both the formulations show similar excretion pattern, which in turn, indicates similarity in their bioavailability. Midpoint of time interval (hr) log of amoxicillin excretion rate Sk-mox Amoxil-Bencard log of amoxicillin excretion rate respectively. It was also observed that both the formulations showed maximum excretion rates in the interval of 5.5 and 4.83 hr (t max ) in terms of mid-point of time (Fig. 2) . Values of other pharmacokinetic parameters of test formulation were also comparable with that of reference formulation. The comparison of all these pharmacokinetic parameters indicates similar bioavailability of amoxicillin for test and reference formulations. The relative bioavailability of amoxicillin from test formulation, in terms of Ae 0−12 , AURC 0-48 and AURC 0-α were found to be 101.63, 100.64 and 100.54 %, respectively. So the test product showed good bioavailability as compared to the reference one.
Statistical analysis for bioequivalence. No significant difference among the parameters was observed when analyzed by paired t-test at 5% level of significance (Table 2 ). ANOVA assessment found no significant formulation, period or sequence effect in the present study (Table 3) .
For bioequivalence decision, R max , Ae 0−12 , AURC 0-48 and AURC 0-α values were taken into consideration for statistical analysis like 90% confidence interval. The estimates of 90% confidence interval for the ratio of these four parameters were found to be within the specified limits of 80 to 125% for log-transformed data as per US FDA requirement for bioequivalence (Table 4) . 13 Thus, it is concluded that test formulation is bioequivalent to reference formulation.
Finally it can be concluded that the test (Skmox ® ) product is bioequivalent to reference (AmoxilBencard ® ) in terms of rate and extent of absorption and therefore interchangeable. Following administra- tion of reference formulation, the cumulative urinary recovery of amoxicillin was found to be 64.34% over 12 hr period in the present study. This recovery is higher compared to the studies on Chilies (43.4% in 24 hr) and Americans (55.8% in 12 hr); but lower than the Germans (68% in 6 hr) and Pakistanis (73.3% in 12 hr). [14] [15] [16] [17] In another study on Americans, the urinary recovery was found to be 70% in 6 hr. 18 These variant recoveries of amoxicillin clearly reflect the ethnic variation in terms of rate and extent of amoxicillin metabolism and excretion, which could be a focus for further study. The exact mechanism of this variation may involve polymorphism of drug transporter, metabolic enzymes or altered drugprotein interaction. These differences in pharmacokinetics may cause some adverse effects in patients and this necessitates the importance of such study on Bangladeshi population to ensure safety and efficacy of this formulation.
